Publication | Closed Access

Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia

Inotuzumab OzogamicinHematological MalignancyCell TherapyPediatric HematologyHematologyImmunologyAutoimmunityAdult T-cell Leukemia-lymphomaImmunotherapyMedicine